ATC codes:
J01FF01
EMLc
Indication
Necrotising fasciitis
ICD11 code:
1B71.Z
INN
Clindamycin
Medicine type
Chemical agent
Antibiotic groups
List type
Core
Formulations
Parenteral > General injections > IV:
150 mg per mL (as phosphate) ;
600 mg per 4 mL (as phosphate) (EML)
;
900 mg per 6 mL (as phosphate) (EML)
Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) (EMLc)
Oral > Solid: 150 mg (as hydrochloride)
Oral > Liquid: 75 mg per 5 mL powder for oral liquid (as palmitate hydrochloride) (EMLc)
Oral > Solid: 150 mg (as hydrochloride)
Sex
All
Age
Also recommended for children
Therapeutic alternatives
The recommendation is for this specific medicine
Patent information
Patents have expired in most jurisdictions
Read more
about patents.
Wikipedia
DrugBank
Expert Committee recommendation
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended:
- the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc.
- replacing the oral liquid formulation of clindamycin (oral liquid 75 mg/5 mL) with powder for oral liquid 75 mg/5 mL (as palmitate hydrochloride) on the EML and EMLc.
- the addition of new strength formulations of IV vancomycin (500 mg, 1 g (as hydrochloride) on the EMLc.
Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended that the range of strengths of metronidazole tablets be replaced with reference to specific strengths on the EML and EMLc.
EML recommendations: Necrotising fasciitis
First choice
Second choice
First choice
metronidazole
co-prescribed with
ceftriaxone
clindamycin co-prescribed with piperacillin + tazobactam
vancomycin
clindamycin co-prescribed with piperacillin + tazobactam
vancomycin
Second choice